Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA

Charles L. Bennett, Oliver A. Sartor, James O. Armitage, Hagop Kantarjian

Research output: Contribution to journal › Comment/debate › peer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA'. Together they form a unique fingerprint.